It is noteworthy, that MG-specific Activities of Daily Living (MG-ADL) and quality of life measured by the Myasthenia gravis-specific 15-item Quality of Life revised scale (MG-QoL15r) were among the primary and secondary outcome measures in clinical trials for the complement inhibitors and neonatal Fc receptor (FcRn) inhibitors [20–22]. The gene discussed is FCGRT; the disease is myasthenia gravis.